和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

已收盘 01-14 16:00:00 EST

15.30

+0.35

+2.34%

盘后15.30

+0.000.00%

19:08 EST

最高15.37	最低14.84	成交量14.42万
今开14.98	昨收14.95	日振幅3.55%
总市值26.69亿	流通市值15.91亿	总股本1.74亿
成交额218.60万	换手率0.14%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":15.3,"timestamp":1768424400000,"preClose":14.95,"halted":0,"volume":144232,"hourTrading":{"tag":"盘后","latestPrice":15.3,"preClose":15.3,"latestTime":"19:08 EST","volume":280,"amount":4273.874,"timestamp":1768435685122},"delay":0,"changeRate":0.02341137123745829,"floatShares":104000000,"shares":174433934,"eps":2.649215,"marketStatus":"已收盘","change":0.35,"latestTime":"01-14 16:00:00 EST","open":14.98,"high":15.37,"low":14.84,"amount":2185971.682312,"amplitude":0.035452,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.649215,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768467600000},"marketStatusCode":5,"adr":1,"adrRate":5,"listingDate":1458187200000,"exchange":"NASDAQ","adjPreClose":14.95,"preHourTrading":{"tag":"盘前","latestPrice":14.7,"preClose":14.95,"latestTime":"08:42 EST","volume":2460,"amount":36691.8102,"timestamp":1768398171284},"postHourTrading":{"tag":"盘后","latestPrice":15.3,"preClose":15.3,"latestTime":"19:08 EST","volume":280,"amount":4273.874,"timestamp":1768435685122},"volumeRatio":2.143573,"impliedVol":0.2938,"impliedVolPercentile":0.4542},"requestUrl":"/m/hq/s/HCM","defaultTab":"news","newsList":[{"id":"2603662471","title":"和黄医药盘中涨超3% SACHI III期研究结果于《柳叶刀》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662471","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603662471?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:40","pubTimestamp":1768444800,"startTime":"0","endTime":"0","summary":"　　和黄医药盘中涨超3%，截至发稿，股价上涨2.39%，现报23.98港元，成交额7741.10万港元。　　据和黄医药官微消息，1月14日，和黄医药宣布SACHI III期研究的结果于《柳叶刀 》发表。　　据介绍，赛沃替尼是一种强效、高选择性的口服MET TKI，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-15/doc-inhhiyxt4368442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1588","BK1587","BK4585","HCM","BK4007","BK4531","BK4588","BK4134","III","00013","BK1191"],"gpt_icon":0},{"id":"2603253613","title":"百时美施贵宝宣布评估玛伐凯泰治疗青少年有症状的梗阻性肥厚型心肌病（oHCM）的III 期临床试验SCOUT-HCM取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2603253613","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603253613?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:55","pubTimestamp":1768391700,"startTime":"0","endTime":"0","summary":"SCOUT-HCM 的阳性研究结果展现了玛伐凯泰有望成为首个用于青少年 oHCM 患者的心肌肌球蛋白抑制剂。青少年oHCM严重损害健康，主要临床表现与运动耐量下降相关。在欧盟，玛伐凯泰获批用于治疗有症状的NYHA心功能分级II-III级的梗阻性肥厚型心肌病成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4863243_ZH63243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1074936037.SGD","LU1670710588.SGD","LU0306806265.USD","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU0868494617.USD","LU1670711123.USD","LU0061475181.USD","IE00B2B36J28.USD","LU0306807586.USD","LU1571399168.USD","LU1868837300.USD","BK4559","LU0114720955.EUR","LU0225284248.USD","BK4134","LU1093756325.SGD","LU1585245621.USD","LU0096364046.USD","LU1093756168.USD","LU1868837136.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU1261432733.SGD","BK4534","LU0321505439.SGD","LU0321505868.SGD","BK4585","LU0456855351.SGD","HCM","IE00BJJMRZ35.SGD","BMY","LU0985481810.HKD","LU1868836914.USD","LU1868836591.USD","LU0225771236.USD","IE0002141913.USD","LU1718418525.SGD","LU1323610961.USD","LU2242652126.USD","BK4588","LU0267386448.USD","LU2125154935.USD","LU0237698245.USD","LU2242646821.SGD","LU1430594728.SGD","III","LU1670710661.SGD","IE0009355771.USD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2603666888","title":"和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603666888","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603666888?lang=zh_cn&edition=full","pubTime":"2026-01-14 12:11","pubTimestamp":1768363890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。中国医学科学院肿瘤医院的王洁教授亦为SACHI 研究的联合主要研究者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013","BK4531","BK4588","BK4134","BK1588","III","BK1191","BK1587","BK4007","BK4585"],"gpt_icon":0},{"id":"2602207113","title":"多重利好刺激股价走出“五连阳”，“躲过牛市”的和黄医药(00013)迎来反转时刻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602207113","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602207113?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:41","pubTimestamp":1767958896,"startTime":"0","endTime":"0","summary":"相较之下，作为一家手握3款商业化创新药并拥有首创抗体靶向偶联药物的创新药企，和黄医药却最终以8.56%的年度跌幅收场，显著跑输指数。去年8月7日美股盘前，和黄医药公布了其2025年中报业绩。最新数据显示，和黄医药的港股通持股比例已达27.28%。这便是和黄医药在25H2期内股价最大回撤幅度高达35.12%的重要原因之一。根据此前II期研究结果，索乐匹尼布针对wAIHA的整体应答率为66.7%，并展现出良好的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1588","BK4585","BK4588","BK4007","HCM","00013","BK1587","BK4531"],"gpt_icon":0},{"id":"2601480429","title":"和黄医药盘中异动 早盘快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601480429","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601480429?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:46","pubTimestamp":1767797189,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日22时46分，和黄医药股票出现异动，股价急速上涨5.02%。截至发稿，该股报14.44美元/股，成交量7672股，换手率0.00%，振幅1.64%。和黄医药股票所在的制药行业中，整体涨幅为2.39%。和黄医药公司简介：和黄医药（中国）有限公司是一家生物制药公司，致力于发现、开发和商业化用于治疗癌症和免疫疾病的靶向疗法和免疫疗法。该公司目前在全球范围内拥有多个临床研究的癌症候选药物组合，并在其中国本土市场拥有广泛的商业基础设施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010722462997a13368&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010722462997a13368&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","BK4588","BK4585","BK4531","BK4007"],"gpt_icon":0},{"id":"2601291804","title":"索乐匹尼布取得突破性进展！和黄医药股价涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601291804","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601291804?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:04","pubTimestamp":1767787448,"startTime":"0","endTime":"0","summary":"另值得关注的是，除了温抗体型自身免疫性溶血性贫血以外，索乐匹尼布治疗免疫性血小板减少症的研究亦正在进行中。和黄医药透露，公司计划于2026年上半年重新提交索乐匹尼布，用于二线治疗免疫性血小板减少症的新药上市申请。综合来看，索乐匹尼布具有不错的商业化前景，后续若其在温抗体型自身免疫性溶血性贫血、免疫性血小板减少症两大适应症的新药上市申请获成功，将有望为公司业绩增长贡献助力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107200638a6fead82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107200638a6fead82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","BK4588","BK4007","BK4531","00013","BK4585"],"gpt_icon":0},{"id":"2601878841","title":"和黄医药(00013)宣布索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的 ESLIM-02中国研究的III期阶段取得阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878841","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878841?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:03","pubTimestamp":1767744211,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血成人患者的ESLIM-02研究的III期注册阶段已达到第5至 24周治疗期间持久血红蛋白应答这一主要终点。ESLIM-02研究的完整数据将提交于近期的学术会议上发表。和黄医药计划于2026年上半年向中国国家药品监督管理局提交索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013","BK1588","III","BK1587","BK4585","BK4531","BK1191","BK4134","BK4588","BK4007"],"gpt_icon":0},{"id":"2601078362","title":"和黄医药(00013)启动现正进行中的索凡替尼联合卡瑞利珠单抗用于治疗初治胰腺导管腺癌研究的III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2601078362","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601078362?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:09","pubTimestamp":1767571757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，公司今日宣布启动索凡替尼联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨用于一线治疗转移性胰腺导管腺癌患者的中国II/III期研究的III期部分。首名患者已于2025年12月30日接受首次给药治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK4134","HCM","BK1191","BK4588","III","BK4585","BK1588","BK4531","00013","BK4007"],"gpt_icon":1},{"id":"2595465795","title":"和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2595465795","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595465795?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:05","pubTimestamp":1767089147,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，赛沃替尼用于经过至少2种治疗后失败的MET基因扩增的局部晚期或转移性胃癌或胃食道连接部腺癌成人患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。该新药上市申请是基于一项在中国开展的赛沃替尼用于治疗伴有MET扩增的胃癌患者的单臂、多中心、开放标签的II期注册研究的数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU1291159041.SGD","LU1989771016.USD","MET","BK1587","LU1989772923.USD","LU1989772840.SGD","HCM","BK4585","BK4531","BK4162","BK1588","BK4588","BK1191","LU1496350502.SGD","00013"],"gpt_icon":0},{"id":"2595788714","title":"和黄医药(00013)宣布凡瑞格拉替尼 (HMPL-453) 用于二线治疗肝内胆管癌的中国新药上市申请获受理并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788714","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788714?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:36","pubTimestamp":1766997386,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，凡瑞格拉替尼 用于既往接受过系统性治疗，且具有成纤维细胞生长因子受体2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌成人患者的新药上市申请已获中国国家药品监督管理局受理 ，并获纳入优先审评。凡瑞格拉替尼是一种新型、选择性的FGFR1 、2和3口服抑制剂。近年来，肝内胆管癌发病率呈持续上升趋势，5年总生存率约9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013)宣布凡瑞格拉替尼 (HMPL-453) 用于二线治疗肝内胆管癌的中国新药上市申请获受理并获纳入优先审评","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4588","BK1191","BK4585","00013","BK4007","BK1587","HCM","BK1588"],"gpt_icon":0},{"id":"2592956602","title":"和黄医药(00013)启动ATTC候选药物HMPL-A251用于治疗实体瘤的全球临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2592956602","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592956602?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:15","pubTimestamp":1765930513,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，启动HMPL-A251的全球I期临床开发项目。这项首个人体试验是一项 I/IIa 期、开放标签、多中心临床研究，旨在评估HMPL-A251单药用于治疗不可切除、伴有HER2 表达的晚期或转移性实体瘤成人患者。次要指标包括初步抗肿瘤活性、药代动力学特征以及HMPL-A251的免疫原性。HMPL-A251是和黄医药新一代ATTC平台旗下首个进入临床开发阶段的候选药物。HMPL-A251 的临床前数据已于2025年AACR-NCI-EORTC分子靶向和癌症治疗国际会议上公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013)启动ATTC候选药物HMPL-A251用于治疗实体瘤的全球临床开发","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4588","BK1191","BK4585","00013","BK4007","BK1587","HCM","BK1588"],"gpt_icon":0},{"id":"2589804367","title":"和黄医药(00013)：达唯珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589804367","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589804367?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:13","pubTimestamp":1765152816,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，经过与中国国家医疗保障局(国家医保局)的医保续约，爱优特®(ELUNATE®)、沃瑞沙®(ORPATHYS®)和苏泰达®(SULANDA®)将继续获纳入自2026年1月1日起生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》(国家医保药品目录)。此外，达唯珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录(简称商保创新药目录)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00013","BK1588","BK4531","BK4585","BK4588","BK4007","BK1587","HCM"],"gpt_icon":0},{"id":"2586729952","title":"和黄医药(00013)将于2025年欧洲肿瘤内科学会 (ESMO) 亚洲年会和 2025年美国血液学会 (ASH) 年会公布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2586729952","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586729952?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:05","pubTimestamp":1764201920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，和黄医药自主研发的化合物的数项研究的最新及更新后的数据将于2025年12月5日至7日在新加坡召开的欧洲肿瘤内科学会亚洲年会，以及 2025年12月6日至9日在美国奥兰多召开的美国血液学会年会上公布。抗CD47单克隆抗体HMPL-A83用于治疗晚期实体瘤的首个人体临床试验结果，以及呋喹替尼 联合信迪利单抗用于二线治疗局部晚期或转移性肾细胞癌的FRUSICA-2注册研究中II期部分的结果将于 2025年ESMO亚洲年会公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ASH","BK4007","LU2463526074.USD","BK4588","00013","BK4531","BK1588","BK1587","BK1191","BK4585","HCM","BK4109"],"gpt_icon":0},{"id":"2582317693","title":"年内股价涨幅收窄至5%，“躲过牛市”的和黄医药(00013)何时反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582317693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582317693?lang=zh_cn&edition=full","pubTime":"2025-11-12 10:11","pubTimestamp":1762913496,"startTime":"0","endTime":"0","summary":"今年以来，在港股创新药牛市带动下，恒生医疗保健指数年初至今最高涨幅达到102.6%，即使经过10月以来的大幅回调，该涨幅也有70.57%。相较之下，手握3款商业化创新药并拥有首创抗体靶向偶联药物的和黄医药却似乎“被市场遗忘”。该公司股价今年年初至今最高涨幅仅36.36%，并且“跟跌不跟涨”，在近期港股创新药板块整体回调期涨幅继续收窄至仅剩5.19%。8月7日美股盘前，和黄医药公布了其2025年中报业绩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1191","BK4531","BK4588","HCM","00013","BK4585","BK1588","BK4007"],"gpt_icon":0},{"id":"2582484474","title":"东方证券：维持和黄医药(00013)“买入”评级 全新ATTC平台激发创新活力","url":"https://stock-news.laohu8.com/highlight/detail?id=2582484474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582484474?lang=zh_cn&edition=full","pubTime":"2025-11-10 14:17","pubTimestamp":1762755461,"startTime":"0","endTime":"0","summary":"公司近期举办研发日活动，介绍癌症和免疫疾病治疗方面的最新进展，包括全新ATTC平台以及管线情况。首个候选药物初步展现全面的抗肿瘤活性HMPL-A251为ATTC平台中的首款候选药物，将PI3K/PIKK抑制剂作为有效载荷与HER2抗体偶联，因此该药物同时靶向HER2和PI3K通路，起到协同抗肿瘤作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","03958","600958","00013"],"gpt_icon":0},{"id":"2581023150","title":"中金：维持和黄医药(00013)跑赢行业评级 目标价30港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581023150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581023150?lang=zh_cn&edition=full","pubTime":"2025-11-07 09:16","pubTimestamp":1762478212,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基本维持和黄医药2025年/2026年归母净利润预测3.66亿美元/0.35亿美元。该行维持跑赢行业评级，基于DCF模型，维持目标价30港币不变，较当前股价有23.9%的上行空间。此外，公司预计将于1H26和2H26分别启动另外两个ATTC分子A580和A830的中美I期研究。ATTC首个候选分子HMPL-A251于研发日公开亮相，早期数据展现潜力ATTC为和黄医药利用其长期以来在小分子领域的经验探索的新颖药物形式。该行认为其有望成为乳腺癌和多种癌种的潜力疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"gpt_icon":0},{"id":"2581738799","title":"和黄医药(00013)宣布沃瑞沙®和泰瑞沙®联合疗法用于治疗泰瑞沙®治疗后疾病进展的伴有 MET过表达和/或扩增的特定肺癌患者的SAFFRON全球III期研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2581738799","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581738799?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:13","pubTimestamp":1762301600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，宣布SAFFRON研究已完成患者入组。SAFFRON研究一项开放标签、随机、全球多中心III期研究，旨在评估沃瑞沙联合泰瑞沙口服治疗对比铂类双药化疗用于治疗接受一线或二线泰瑞沙治疗作为最近的治疗后疾病进展的EGFR突变、伴有MET过表达和/或扩增的局部晚期或转移性非小细胞肺癌。若取得理想的结果，其数据将有望支持向全球监管机构提交沃瑞沙和泰瑞沙联合疗法的监管注册申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","III","00013","MET","BK4531","BK1191","LU1496350502.SGD","BK4007","LU1291159041.SGD","LU1989772923.USD","BK4588","BK1587","BK4162","BK4134","HCM","BK1588","LU1989772840.SGD","LU1989771016.USD"],"gpt_icon":0},{"id":"2580725271","title":"和黄医药(00013.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580725271","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580725271?lang=zh_cn&edition=full","pubTime":"2025-11-04 10:31","pubTimestamp":1762223460,"startTime":"0","endTime":"0","summary":"每经AI快讯，和黄医药(00013.HK)涨超3%，截至发稿，涨2.95%，报24.46港元，成交额6552.25万港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-11-04/doc-infwfawx0552315.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-04/doc-infwfawx0552315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1587","BK4585","BK1588","BK4531","BK4588","HCM","BK4007","00013","BK1191"],"gpt_icon":0},{"id":"2580429840","title":"美股异动丨和黄医药盘前涨超2%，预计年底推动候选药物HMPL-A251进入临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2580429840","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580429840?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:27","pubTimestamp":1762162023,"startTime":"0","endTime":"0","summary":"和黄医药盘前涨超2%，报15美元；H股今日收涨2.15%，报23.76港元。　　消息面上，和黄医药日前举办了投资者会议，分享其创新ATTC平台及一系列产品最新关键研发和业务进展。其中ATTC平台首个候选药物HMPL-A251，在体外实验中其PI3K/PIKK抑制剂有效载荷在多种肿瘤细胞系中展现出高选择性和强效的抗肿瘤活性。和黄医药计划采取以数据为导向的策略，从2025年底开始推动HMPL-A251进入临床开发，初期研究将评估该候选药物在伴有不同HER2及PAM改变状态的多个瘤种中的表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251103/31762965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["HCM","BK4531","BK1588","BK1191","BK1587","BK4007","00013","BK4588","BK4585"],"gpt_icon":0},{"id":"2580723774","title":"和黄医药(00013)举办最新研发进展投资者会议分享产品管线及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2580723774","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580723774?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:06","pubTimestamp":1762128413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，于2025年10月31日举行的投资者会议中分享最新关键研发和业务进展。此次活动重点展示了和黄医药在推进创新癌症和免疫疾病治疗方面的最新进展，包括介绍其新一代抗体靶向偶联药物(ATTC)平台，以及后期管线候选药物的最新进展。和黄医药研发负责人兼首席医学官石明博士表示：“满足癌症和免疫疾病领域关键未被满足的医学需求是和黄医药的使命所在，驱动着我们持续致力推进创新疗法。ATTC平台有望重新定义癌症精准治疗，依托我们坚实的产品管线和合作策略，我们有信心能够为全球患者提供具有潜在变革性的癌症和免疫疾病治疗方案。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK1587","BK4531","BK1588","BK4585","HCM","BK4007","BK4588","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0873},{"period":"1month","weight":0.114},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.1467},{"period":"1year","weight":0.0303},{"period":"ytd","weight":0.1215}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.031055},{"month":2,"riseRate":0.444444,"avgChangeRate":0.016796},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.014296},{"month":4,"riseRate":0.5,"avgChangeRate":0.03686},{"month":5,"riseRate":0.4,"avgChangeRate":-0.069594},{"month":6,"riseRate":0.7,"avgChangeRate":0.077435},{"month":7,"riseRate":0.6,"avgChangeRate":0.053079},{"month":8,"riseRate":0.4,"avgChangeRate":0.002476},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017634},{"month":10,"riseRate":0.5,"avgChangeRate":-0.007604},{"month":11,"riseRate":0.7,"avgChangeRate":0.110086},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016892}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}